Indications
Acute and recovery periods of severe TBI and ischemic stroke, recovery period of hemorrhagic stroke, occurring with focal hemispheric symptoms or symptoms of brain stem damage;
$29.00
Active ingredient: | |
---|---|
Dosage form: |
Acute and recovery periods of severe TBI and ischemic stroke, recovery period of hemorrhagic stroke, occurring with focal hemispheric symptoms or symptoms of brain stem damage;
of 1 ml contains:
active substance:
glycerylphosphorylcholine hydrate 250 mg,
excipients:
water for injection
>
1 ml contains:
Active ingredient:
glycerylphosphorylcholine hydrate 250 mg,
excipients:
water for injection
Pharmacodynamics
Cereton provides the synthesis of acetylcholine and phosphatidylcholine in neuronal membranes, improves blood flow and enhances metabolic processes in the central nervous system, activates the reticular formation.
Increases the linear velocity of blood flow on the side of traumatic brain damage, contributes to the normalization of spatiotemporal characteristics: spontaneous bioelectric activity of the brain, regression of focal neurological symptoms and restoration of consciousness; has a positive effect on the cognitive and behavioral responses of patients with vascular diseases of the brain (dyscirculatory encephalopathy and residual phenomena of cerebral circulatory disorders). It stimulates the dose-dependent release of acetylcholine under physiological conditions, improves synaptic transmission, and receptor function. It does not affect the reproductive cycle and has no teratogenic, mutagenic effect.
It has a preventive and corrective effect on pathogenetic factors of involutional psychoorganic syndrome, changes the phospholipid composition of neuronal membranes: it participates in the synthesis of phosphatidylcholine (membrane phospholipid), improves the plasticity of neuronal membranes.
Pharmacokinetics
When taken parenterally (10 mg/kg), Ceretone mainly accumulates in the brain, lungs, and liver. Absorption – 88%, easily penetrates the blood-brain barrier (when taken orally, the concentration in the brain is 45% of that in plasma).85% of the drug is excreted by the lungs in the form of carbon dioxide, the remaining amount (15%) is excreted by the kidneys and through the intestines.
Acute and recovery periods of severe TBI and ischemic stroke, recovery period of hemorrhagic stroke, occurring with focal hemispheric symptoms or symptoms of brain stem damage;
It is contraindicated during pregnancy and lactation.
Nausea may occur (mainly as a result of dopaminergic activation), in this case, the dose of the drug is reduced.
From the digestive system: constipation, diarrhea, dryness of the oral mucosa, pharyngitis.
Nervous system disorders: headache, drowsiness, insomnia, aggressiveness, anxiety, nervousness, cerebral ischemia, convulsions, dizziness.
Skin disorders: rash, urticaria.
Other: pain at the injection site, increased urination.
Allergic reactions.
No significant interaction with other drugs was detected.
In acute conditions, the solution is administered intravenously (slowly) or deeply intramuscularly at 1000 mg (1 ampoule) per day for 10-15 days.
Symptoms: nausea may occur.
Treatment: symptomatic therapy.
Ceretone does not affect the speed of psychomotor reactions.
Solution for intravenous and intramuscular use
In a dark place, at a temperature not exceeding 25 °C
5 years
Choline alfoscerate
By prescription
solution for injection and infusion
Reviews
There are no reviews yet